ETBX-051; adenoviral brachyury vaccine

BIOLOGICAL2 trials

Sponsors

National Cancer Institute (NCI)

Conditions

Breast CancerColon CancerLung CancerNeoplasmsProstate CancerProstatic CancerProstatic Neoplasms

Phase 1

Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer

CompletedNCT03384316

National Cancer Institute (NCI)Breast Cancer, Colon Cancer, Lung Cancer +2

Start: 2018-01-31End: 2020-08-24Updated: 2020-09-09

Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines

CompletedNCT03481816

National Cancer Institute (NCI)Prostatic Cancer, Prostatic Neoplasms

Start: 2018-07-24End: 2021-03-09Updated: 2021-05-19

Related Papers

Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer

Journal for ImmunoTherapy of Cancer2021-09-0136 citations

Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC)

Journal for ImmunoTherapy of Cancer2021-03-0159 citations